NuCana plc

Equities

NCNA

US67022C2052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 03/07/2024 am IST			5-day change	1st Jan Change
2.57 ^USD	-7.22%		-13.03%	-65.25%

02/07	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT
01/07	European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	MT

NuCana plc Appoints Andrew Kay as Chairman of its Board of Directors

December 22, 2020 at 02:31 am IST

NuCana plc announced the appointment of Andrew Kay as Chairman of its Board of Directors. Andrew Kay brings more than 30 years of experience in building and leading biotechnology and pharmaceutical companies. Andrew currently serves as Chairman of the Board of NeRRe Therapeutics and Blueberry Therapeutics.

Latest news about NuCana plc

European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	02/07	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	01/07	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	28/06	MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading	20/06	MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	17/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	11/06	MT
Top Premarket Decliners	10/06	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	07/06	MT
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	31/05	MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	28/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	24/05	MT
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	24/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	21/05	MT
NuCana plc Reports Earnings Results for the First Quarter Ended March 31, 2024	17/05	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	10/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	09/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	08/05	MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday	07/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	01/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	26/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	25/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	24/04	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	22/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	19/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	17/04	MT

Chart NuCana plc

Duration

Period

More charts

Company Profile

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3â-deoxyadenosine (3â-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Companyâs subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.57 USD

Average target price

209 USD

Spread / Average Target

+8,032.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NUCANA PLC	-65.25%	62.23L
VERTEX PHARMACEUTICALS INCORPORATED	+16.44%	12TCr
REGENERON PHARMACEUTICALS, INC.	+18.94%	11TCr
ARGENX SE	+19.62%	2.57TCr
BIONTECH SE	-25.37%	1.9TCr
GENMAB A/S	-20.21%	1.58TCr
BEIGENE, LTD.	-20.20%	1.53TCr
WUXI APPTEC CO., LTD.	-47.37%	1.49TCr
SAREPTA THERAPEUTICS, INC.	+59.91%	1.48TCr
NEUROCRINE BIOSCIENCES, INC.	+4.35%	1.41TCr

Bio Therapeutic Drugs